Literature DB >> 21804589

Abiraterone acetate.

Christopher J Logothetis, Eleni Efstathiou, Fil Manuguid, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21804589     DOI： 10.1038/nrd3516

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  6 in total

Review 1.  Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.

Authors:  Gerhardt Attard; Arie S Belldegrun; Johann S de Bono
Journal:  BJU Int       Date:  2005-12       Impact factor: 5.588

2.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

3.  A new therapy paradigm for prostate cancer founded on clinical observations.

Authors:  Eleni Efstathiou; Christopher J Logothetis
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

4.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

Review 5.  Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.

Authors:  Gerhardt Attard; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

6.  Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.

Authors:  G A Potter; S E Barrie; M Jarman; M G Rowlands
Journal:  J Med Chem       Date:  1995-06-23       Impact factor: 7.446
  6 in total
  6 in total

Review 1.  Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Authors:  Anil Kapoor; Christopher Wu; Bobby Shayegan; Adrian P Rybak
Journal:  Can Urol Assoc J       Date:  2016-12-12       Impact factor: 1.862

2.  Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry.

Authors:  Tianzhu Zang; Daniel Tamae; Clementina Mesaros; Qingqing Wang; Meng Huang; Ian A Blair; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2016-08-12       Impact factor: 4.292

3.  Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).

Authors:  Tianzhu Zang; Kshitij Verma; Mo Chen; Yi Jin; Paul C Trippier; Trevor M Penning
Journal:  Chem Biol Interact       Date:  2014-12-31       Impact factor: 5.192

4.  Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

Authors:  Damoun Safarpour; Shabnam Pakneshan; Fattaneh A Tavassoli
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

5.  Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.

Authors:  Sifeng Qu; Kendric Wang; Hui Xue; Yuwei Wang; Rebecca Wu; Chengfei Liu; Allen C Gao; Peter W Gout; Colin C Collins; Yuzhuo Wang
Journal:  Mol Oncol       Date:  2013-12-15       Impact factor: 6.603

6.  Reagent-controlled regiodivergent ring expansions of steroids.

Authors:  Manwika Charaschanya; Jeffrey Aubé
Journal:  Nat Commun       Date:  2018-03-05       Impact factor: 14.919
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.